Company Focus
Biogen
Latest Biogen News
Biotechnology
US clinical-stage biotech Nura Bio, which is developing neuroprotective small molecule therapies, today announced the completion of a $73.8 million Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs. 22 June 2026
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing atacicept and other targeted therapies for serious immunological and kidney diseases with high unmet medical need.
Latest News & Features of interest to Biogen
Biotechnology
French genetic medicines company Cyllene Therapeutics has raised 33 million euros ($38 million) in series C financing to support development of its lead neuro-urology candidate EG110A, as the company rebrands from EG 427 and moves closer to late-stage clinical testing. 8 July 2026
Pharmaceutical
Florida, USA-based clinical-stage biopharma DemeRx has appointed Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from pre-clinical research through clinical development. 8 July 2026
Pharmaceutical
Italian drugmaker Italfarmaco has presented new clinical data supporting the long-term use of Duvyzat (givinostat) in Duchenne muscular dystrophy (DMD), including MRI findings suggesting the therapy may help preserve muscle tissue and reduce fat infiltration. 7 July 2026
Biotechnology
UK biotech Compass Pathways today announced the 26-week results (Part B) from its second ongoing Phase III COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD) which confirm COMP360’s rapid onset and durable profile. 7 July 2026
Pharmaceutical
US drug developer Crinetics Pharmaceuticals saw its shares rocket 99% to $83.64 in pre-market activity today, following the news of a takeover bid from Vertex Pharmaceuticals. 7 July 2026
Generics
Glenmark Pharmaceuticals has launched a US generic version of Zyprexa (olanzapine) for injection, adding another hospital medicine to its growing injectables portfolio as the company continues to strengthen its presence in the institutional market. 6 July 2026
Biotechnology
Swiss biotech Pharvaris has moved a step closer to the US market after the Food and Drug Administration (FDA) accepted its New Drug Application for deucrictibant immediate-release capsules as an on-demand treatment for hereditary angioedema (HAE) attacks. 6 July 2026
Biotechnology
In last week’s news, US biotech Replimune’s resubmitted biologicals license application (BLA) for RP1 (vusolimogene oderparepvec) was accepted by the Food and Drug Administration. On the M&A front, Zymeworks announced plans to acquire Theravance Biopharma and its key product Yupelri for COPD. French drugmaker Ipsen revealed plans to buy Kartos Therapeutics for an upfront $450 million, gaining rights to the latter’s navtemadlin. Ipsen then went to bid up to $1.75 billion for Memo Therapeutics and potravitug. Also, BioCrsyt Pharma revealed plans to wind down its internal discovery programs. 5 July 2026
Biotechnology
US drugmaker United Therapeutics yesterday revealed that it has acquired Thymmune Therapeutics, a privately held, pre-clinical stage biotechnology company. 3 July 2026
Biotechnology
As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on patient-reported outcomes to carve out space for Briumvi (ublituximab) in a crowded anti-CD20 monoclonal antibody (MAb) field. 3 July 2026
Latest In Brief for Biogen
Biotechnology
US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion. 20 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze